The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Publication Title
British journal of haematology
Document Type
Article
Publication Date
3-16-2020
Keywords
follicular lymphoma; ibrutinib; rituximab
Abstract
This phase 2 study evaluated the activity and safety of ibrutinib, a Bruton's tyrosine kinase inhibitor, plus rituximab in adults with previously untreated follicular lymphoma. Patients received once-daily ibrutinib 560 mg continuously plus once-weekly rituximab 375 mg/m
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Hematology
COinS
